BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24365090)

  • 1. Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing.
    Kastner R; Zopf A; Preuner S; Pröll J; Niklas N; Foskett P; Valent P; Lion T; Gabriel C
    Eur J Cancer; 2014 Mar; 50(4):793-800. PubMed ID: 24365090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].
    Cayuela JM; Chomel JC; Coiteux V; Dulucq S; Escoffre-Barbe M; Etancelin P; Etienne G; Hayette S; Millot F; Nibourel O; Nicolini FE; Réa D;
    Bull Cancer; 2020 Jan; 107(1):113-128. PubMed ID: 31353136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
    Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
    Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study.
    Kizilors A; Crisà E; Lea N; Passera R; Mian S; Anwar J; Best S; Nicolini FE; Ireland R; Aldouri M; Pocock C; Corbett T; Gale R; Bart-Smith E; Weston-Smith S; Wykes C; Kulasekararaj A; Jackson S; Harrington P; McLornan D; Raj K; Pagliuca A; Mufti GJ; de Lavallade H
    Lancet Haematol; 2019 May; 6(5):e276-e284. PubMed ID: 31036317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.
    Machova Polakova K; Kulvait V; Benesova A; Linhartova J; Klamova H; Jaruskova M; de Benedittis C; Haferlach T; Baccarani M; Martinelli G; Stopka T; Ernst T; Hochhaus A; Kohlmann A; Soverini S
    J Cancer Res Clin Oncol; 2015 May; 141(5):887-99. PubMed ID: 25367136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper.
    Soverini S; Abruzzese E; Bocchia M; Bonifacio M; Galimberti S; Gozzini A; Iurlo A; Luciano L; Pregno P; Rosti G; Saglio G; Stagno F; Tiribelli M; Vigneri P; Barosi G; Breccia M
    J Hematol Oncol; 2019 Dec; 12(1):131. PubMed ID: 31801582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches.
    Preuner S; Barna A; Frommlet F; Czurda S; Konstantin B; Alikian M; Machova Polakova K; Sacha T; Richter J; Lion T; Gabriel C
    Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27136541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
    Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
    BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of BCR-ABL1 mutations that confer tyrosine kinase inhibitor resistance using massively parallel, next generation sequencing.
    Szankasi P; Schumacher JA; Kelley TW
    Ann Hematol; 2016 Jan; 95(2):201-10. PubMed ID: 26555285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper.
    Soverini S; Albano F; Bassan R; Fabbiano F; Ferrara F; Foà R; Olivieri A; Rambaldi A; Rossi G; Sica S; Specchia G; Venditti A; Barosi G; Pane F
    Cancer Med; 2020 May; 9(9):2960-2970. PubMed ID: 32154668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia.
    Preuner S; Mitterbauer G; Mannhalter C; Herndlhofer S; Sperr WR; Valent P; Lion T
    Eur J Cancer; 2012 Jan; 48(2):233-6. PubMed ID: 21955823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia.
    Romzova M; Smitalova D; Tom N; Jurcek T; Culen M; Zackova D; Mayer J; Racil Z
    Br J Haematol; 2020 May; 189(3):469-474. PubMed ID: 32037516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Soverini S; Martelli M; Bavaro L; De Benedittis C; Papayannidis C; Sartor C; Sorà F; Albano F; Galimberti S; Abruzzese E; Annunziata M; Russo S; Stulle M; Imovilli A; Bonifacio M; Maino E; Stagno F; Maria Basilico C; Borlenghi E; Fozza C; Mignone F; Minari R; Stella S; Baccarani M; Cavo M; Martinelli G
    Br J Haematol; 2021 Apr; 193(2):271-279. PubMed ID: 33403687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
    Soverini S; Bavaro L; De Benedittis C; Martelli M; Iurlo A; Orofino N; Sica S; Sorà F; Lunghi F; Ciceri F; Galimberti S; Baratè C; Bonifacio M; Scaffidi L; Castagnetti F; Gugliotta G; Albano F; Russo Rossi AV; Stagno F; di Raimondo F; D'Adda M; di Bona E; Abruzzese E; Binotto G; Sancetta R; Salvucci M; Capodanno I; Girasoli M; Coluzzi S; Attolico I; Musolino C; Calistri E; Annunziata M; Bocchia M; Stella S; Serra A; Errichiello S; Saglio G; Pane F; Vigneri P; Mignone F; Laginestra MA; Pileri SA; Percesepe A; Tenti E; Rosti G; Baccarani M; Cavo M; Martinelli G
    Blood; 2020 Feb; 135(8):534-541. PubMed ID: 31877211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
    Khorashad JS; Kelley TW; Szankasi P; Mason CC; Soverini S; Adrian LT; Eide CA; Zabriskie MS; Lange T; Estrada JC; Pomicter AD; Eiring AM; Kraft IL; Anderson DJ; Gu Z; Alikian M; Reid AG; Foroni L; Marin D; Druker BJ; O'Hare T; Deininger MW
    Blood; 2013 Jan; 121(3):489-98. PubMed ID: 23223358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
    Moore FR; Yang F; Press RD
    Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
    Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M
    BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand.
    Limsuwanachot N; Kongruang A; Rerkamnuaychoke B; Singdong R; Niparuck P; Jootar S; Siriboonpiputtana T
    Asian Pac J Cancer Prev; 2020 Jul; 21(7):2003-2012. PubMed ID: 32711426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
    Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
    Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in Variants in the Structural Domain of BCR-ABL1 Kinase between Chinese Han and Minority Patients with Chronic Myeloid Leukemia by Sanger Sequencing and Next-Generation Sequencing.
    Abulaiti D; Tuerxun N; Wang H; Abulizi P; Zhao F; Liu Y; Hao J
    Cytogenet Genome Res; 2022; 162(4):201-206. PubMed ID: 36167055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.